In The News Posted December 8, 2019 Share Posted December 8, 2019 CAMBRIDGE, Mass., Dec. 8, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced initial data from the Phase 2 PIONEER clinical trial of avapritinib in... View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.